bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
SAN ANTONIO, November 14, 2024--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.
EurekAlert!3d
Novel SOURCE study examining development of early COPD in ages 30 to 55
Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...
manilatimes5d
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Earlier in his career, he served as CFO at multiple publicly-traded biotech companies including Sirna Therapeutics, a genetic ...
Altimmune, Inc: Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...